BioSpace News Archive

Astellas Pharma Inc. announced topline results from the Phase 3 MOONLIGHT 3™ clinical trial in women in mainland China evaluating the long-term safety and tolerability of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause.

Wugen, Inc. announced it will present preclinical data on WU-NK-101, the company’s lead memory natural killer cell therapy product, at the European Society for Medical Oncology Congress 2022, taking place in Paris, France from September 9-13, 2022.

CatalYm announced that the mature results from its Phase 1, first-in-human trial “GDFATHER-1” will be presented in an oral presentation at the European Society for Medical Oncology Congress 2022.